Copy number alterations in prostate tumors and disease aggressiveness
about
Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cellsDLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activityIntegration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition.Copy number alteration burden predicts prostate cancer relapseGenomic alterations on 8p21-p23 are the most frequent genetic events in stage I squamous cell carcinoma of the lungDifference of Genome-Wide Copy Number Alterations between High-Grade Squamous Intraepithelial Lesions and Squamous Cell Carcinomas of the Uterine Cervix.Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratificationThe diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencingThe genomic landscape of prostate cancerWW domain-containing oxidoreductase's role in myriad cancers: clinical significance and future implications.WWOX: a fragile tumor suppressor.Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer.Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy.Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations.Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patientsTumor Suppressor Gene in Breast Cancer, a Historical Perspective and Future Directions
P2860
Q28383203-8FB74032-B0B1-4AEF-9E7E-720AD37FA561Q28385400-053C8DB2-71EB-47B3-BB81-85BDDFC9DE1CQ33670486-E4BFA16E-82A9-49F3-808E-1DEB5FDE3FE5Q34002312-D8D4D42F-187C-4038-A949-60FB7427A47EQ34795438-3208D81C-F7E7-438A-876F-A0A1197124CEQ36343618-977091F9-80C2-448D-9597-89033FB7B02DQ37067529-C4196E6F-AB44-4954-8E2C-80E5EBDC7363Q38090427-688B82E1-5FFA-4CCF-9CEA-AD56B602D36CQ38109474-BC3E3C55-E3DA-44A9-AE76-F5A64DBB072FQ38186582-442B4F8D-54DF-4803-B573-96543FD202F7Q38299692-A6315D63-8F72-472C-B8D7-5A8589040870Q39027992-3AE06752-8208-424B-8026-94FD921B28FAQ41439657-BCE8B358-45C0-406C-B6A0-12D50CDFB23EQ41604310-80B1C113-ADE8-44EC-8E18-73E7A8C67307Q42764596-1B009633-E094-4E67-8713-F7C40F68F759Q57107482-56C98189-47BF-4878-96C0-396D23666286
P2860
Copy number alterations in prostate tumors and disease aggressiveness
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Copy number alterations in prostate tumors and disease aggressiveness
@ast
Copy number alterations in prostate tumors and disease aggressiveness
@en
type
label
Copy number alterations in prostate tumors and disease aggressiveness
@ast
Copy number alterations in prostate tumors and disease aggressiveness
@en
prefLabel
Copy number alterations in prostate tumors and disease aggressiveness
@ast
Copy number alterations in prostate tumors and disease aggressiveness
@en
P2093
P2860
P356
P1476
Copy number alterations in prostate tumors and disease aggressiveness
@en
P2093
Albert M Levin
Benjamin A Rybicki
Christine Neslund-Dudas
Gary K Chen
Graham Casey
Iona Cheng
John S Witte
Sarah Plummer
Yu Chuan Tai
P2860
P356
10.1002/GCC.20932
P577
2011-10-02T00:00:00Z